Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
Metagenomi to present preclinical MGX-001 hemophilia A data at ASH on Dec 14, 2026; global trial still planned for 2027.
What this release says
Metagenomi Therapeutics will give an oral presentation on preclinical data for MGX-001, its lead hemophilia A program, at the 68th ASH Annual Meeting on December 14, 2026. The company says it remains on track to start a global clinical trial in 2027, subject to regulatory clearance. For a shareholder, this is a scientific update on an early-stage program that is not yet in human testing.
Key figures
- Presentation date
- December 14, 2026
- Abstract number
- 952
- Planned trial start
- 2027
Positive for shareholders
- The company plans to present its latest efficacy and safety results to the hematology community.
- The company says the program could offer a one-time treatment that avoids lifelong treatment burden for hemophilia A patients.
Negative for shareholders
- The data are preclinical, so MGX-001 has not yet been tested in patients.
- The planned clinical trial start in 2027 depends on regulatory clearance.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- Preclinical:
- Studies done in laboratories or animals before any testing in human volunteers or patients.
- Hemophilia A:
- An inherited bleeding disorder caused by a shortage of clotting Factor VIII.
- Genome editing:
- Techniques that make targeted changes to a cell's DNA to alter how a gene works.
FAQ
What is Metagenomi Therapeutics presenting at the ASH meeting?
Dr. Alan Brooks will give an oral presentation on preclinical data supporting MGX-001, the company's lead hemophilia A program, at the 68th ASH Annual Meeting.
When does Metagenomi plan to start clinical trials for MGX-001?
The company says it plans to initiate a global clinical trial in 2027, subject to regulatory clearance.
Historical context for MGX
Across the 13 sessions after earlier MGX headlines, the stock closed higher 3 times and lower 8 times, with a median move of 3.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MGX | SPY |
|---|---|---|---|
| Oct 13, 2026 | Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference | -10.1% | -0.0% |
| Sep 1, 2026 | Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference | -0.8% | -0.7% |
| Aug 11, 2026 | Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results | -1.6% | -0.3% |
| Jul 7, 2026 | Chardan Capital Markets resumed coverage on Metagenomi Therapeutics with a new price target | +5.6% | -0.5% |
| May 28, 2026 | Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference | +3.7% | +0.6% |
| May 12, 2026 | Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results | +0.0% | -0.2% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2024
Follow MGX and get a push notification the moment its next story breaks.